To evaluate the safety and effectiveness of Ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade A…

Phase IIIvonescimabIntraperitoneal+3 more

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07753824

Phase 2

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.

IvonescimabClear Cell Renal Carcinoma

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06940518